"We have done a head-to-head study with exenatide [Amylin's Byetta] and sitagliptin [Merck's Januvia], and I'm sorry to say for DPP-4 lovers that exenatide just destroyed sitagliptin in anything you would want to look at."
-Dr. Ralph DeFronzo (University of Texas Health Science Center, San Antonio, TX) highlighting the comparative advantages of GLP-1 agonists over DPP-4 inhibitors for the treatment of type 2 diabetes. At the American Diabetes Association’s (ADA) 72nd Scientific Sessions (see this month’s conference pearls), June 8-12, Philadelphia, PA.
“In my opinion, time in range is the best measure of glucose control.”
-Dr. Aaron Kowalski (JDRF, New York) during a joint webcast announcing Medtronic’s new partnership with JDRF and the Helmsley Charitable Trust (see this month’s new now next), June 5, 2012.
“The most interesting area of diabetes is the role of psychosocial issues in glycemic control…that is a huge barrier.”
-Dr. John Buse (University of North Carolina School of Medicine, Chapel Hill, NC) at the Sixth Annual diaTribe/Close Concerns/TCOYD Diabetes Forum (see this month’s new now next), June 11, 2012, Philadelphia, PA.